key: cord-0769835-2x9s768c
authors: Henrina, J.; Putra, I. C. S.; Cahyadi, I.; Gunawan, H. F. H.; Cahyadi, A.; Suciadi, L. P.
title: Clinical Characteristics and Outcomes of Venous Thromboembolism in Patients Hospitalized for COVID-19: Systematic Review and Meta-Analysis
date: 2020-06-16
journal: nan
DOI: 10.1101/2020.06.14.20130922
sha: e5eda77b5add970a692565f0bfd52697dacd1ed2
doc_id: 769835
cord_uid: 2x9s768c

Objective: To investigate the clinical characteristics and outcomes of Coronavirus Disease of 2019 (COVID-19) patients complicated with venous thromboembolism (VTE) Method: We performed a comprehensive literature search of several databases to find studies that assessed VTE in hospitalized COVID-19 patients with a primary outcome of all-cause mortality and secondary outcomes of intensive care unit (ICU) admission and mechanical ventilation. We also evaluated the clinical characteristics of VTE sufferers. Results: Eight studies have been included with a total of 1237 pooled subjects. Venous thromboembolism was associated with higher mortality (2.48 (1.35, 4.55), p=0.003; I2 5%, p=0.35) after we performed sensitivity analysis, ICU admission (RR 2.32 (1.53, 3.52), p<0.0001; 80%, p <0.0001), and mechanical ventilation need (RR 2.73 (1.56, 4.78), p=0.0004; 77%, p=0.001). Furthermore, it was also associated to male gender (RR 1.21 (1.08, 1.35), p=0.0007; I2 12%, p=0.34), higher white blood cells count (MD 1.24 (0.08, 2.41), 0.04; I2 0%; 0.26), D-dimer (MD 4.49 (2.74, 6.25), p<0.00001; I2 67%, p=0.009) and LDH levels (MD 70.93 (19.33, 122.54), p<0.007; I2 21%, p=0.28). In addition, after sensitivity analysis was conducted, VTE also associated with older age (MD 2.79 (0.06, 5.53), p=0.05; I2 25%, p=0.24) and higher CRP levels (MD 2.57 (0.88, 4.26); p=0.003; I2 0%, p=0.96). Conclusion: Venous thromboembolism in COVID-19 patients was associated with increased mortality, ICU admission, and mechanical ventilation requirement. Male gender, older age, higher levels of biomarkers, including WBC count, D-Dimer, and LDH were also being considerably risks for developing VTE in COVID-19 patients during hospitalization.

Coronavirus disease of 2019 (COVID-19) is a highly contagious respiratory disease caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) resulting in a global pandemic status. As of this paper writing, it has already claimed more than 400.000 lives and infected approximately 7 million people throughout the world (1). As the name implies, many aspects of this multifaceted disease are being explored. Notably, the coagulopathy associated with COVID-19, in which the evidence is still emerging. (2) (3) (4) (5) A previous study has shown that D-dimer, a primary marker of coagulopathy, was associated with higher mortality.(5) Furthermore, lung dissection and autopsy from COVID-19 decedents showed pulmonary microthrombi formation. (4, 6) Therefore, several authors argued that Acute Respiratory Distress Syndrome (ARDS), which is the most common complication of COVID-19, is caused by pulmonary endothelial dysfunction identified as pulmonary intravascular coagulopathy (PIC) or pulmonary thrombosis. (7, 8) This argument is substantiated by several findings that the incidence of pulmonary embolism (PE) is more frequent than deep vein thrombosis (DVT). (9) Data from multiple studies have shown a higher incidence of venous thromboembolism (VTE) in hospitalized COVID-19 patients compared to other diseases. (10, 11) This acute vascular complication might potentially affect morbidity and mortality of COVID-19 patients during hospitalization. Nevertheless, a retrospective study conducted by Tang et al. showed that patients with higher D-dimer levels and sepsis-induced coagulopathy (SIC) scores who received heparin have lower mortality rates.(4) However, more prospective studies are needed to confirm this result.

Therefore, the study aimed to systematically investigate the outcomes of hospitalized COVID-19 patients complicated with VTE. We also scrutinized any clinical characteristics which potentially indicated to developing VTE in this population during hospitalization. With this study, we want to determine which COVID-19 patients that have the propensity to develop VTE during hospitalization. Thus, more attention can be given to these patients to reduce morbidity and mortality during hospitalization.

The predefined protocol was used for this review and in line with Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). We systematically searched and identified studies published between 1 January 2020 and 31 May 2020, through electronic searches using MEDLINE, Europe PMC, Proquest, Ebscohost, Google Scholar, Cochrane Central, Clinicaltrial.gov and from preprint websites (Preprint.org and MedRxiV.org). We used Medical Subject Headings (MeSH) and free word to construct our search terms related to venous thromboembolism (venous thromboembolism OR deep vein thrombosis or pulmonary embolism), coronavirus disease of 2019 (COVID-19 and SARS-CoV-2). We identified articles eligible for further review by performing screening of identified titles or abstracts, followed by a full-text review. In the case of multiple publications, the most recent and complete report was included. We finalized the systematic literature review search on 31 May 2020. This study adhered to the PRISMA guideline.

Articles eligibility was assessed by two independent investigators (JH and ICSP).

Discrepancies were resolved by consensus with a third investigator (AC). The inclusion criteria of the article in this study included all research studies involving hospitalized COVID-19 patients experiencing VTE (DVT group and PE group only, non-specified VTE group, and specified VTE group). We excluded commentaries, non-research letter, reviews, and case reports/case series.

A standardized form was used to collect the information that consists of qualitative aspects of identified studies (the first author and publication year, geographic locations, and study design), COVID-19 patients' profile (gender and age), venous thromboembolisms, and comorbidities. Two authors performed data extraction independently (JH and ICSP). The primary outcome of interest was all-cause mortality, and the secondary outcomes of interest were intensive care admission and mechanical ventilation. In addition, we also extracted data regarding clinical characteristics (patient characteristics, comorbidities, sign and symptoms, and laboratory findings). Data that was reported other than mean ± SD was transformed accordingly using the formula created by Wan et al. (12) Statistical analysis

We performed meta-analysis using Review Manager 5.4 (). For dichotomous variables, we calculated the pooled estimates and its 95% confidence interval in the form of risk ratios (RRs) using the Mantel-Haenzel formula. We calculated the pooled estimates for continuous variables in the form of a mean difference (MD) and its standard deviation. To account for interstudy variability regardless of the heterogeneity, we used a random-effects model. We used two-tailed p values with a significance set at 0.05. To assess heterogeneity across studies, we used the inconsistency index (I 2 ) with a value above 50% or p < 0.05 indicates significant heterogeneity. We performed a sensitivity analysis using the leave-one-out method to achieve statistical robustness and find the source of heterogeneity. Finally, to qualitatively detect publication bias, we used an inverted funnel-plot analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 16, 2020. .

Initial systematic database search yielded 365 studies, of which 192 remain after duplicates were excluded. Through title/abstract screening, 170 studies were excluded and left with 22 remaining studies. The final 22 studies were assessed for full-text eligibility, of which 15 of them were excluded due to: one was editorial, two were case reports, three were case-series, one study of PE in non-COVID-19 patients, one study in oupatient COVID-19 patients, and six studies in ICU admitted COVID-19. As a result, only eight studies (n= 1237 subjects) were included in the qualitative and quantitative synthesis. (13) (14) (15) (16) (17) (18) (19) (20) (Figure 1 Clinical characteristics associated with VTE Around 27 variables consist of patient characteristics, comorbidities, VTE risk factors, signs and symptoms, and laboratory findings have been analysed (Table 3 and Table   4 ). However, there were only 8 variables associated with VTE, and three of them only included two studies.

The meta-analysis showed that the incidence of VTE in COVID-19 patients were more common in men (RR 1.21 (1.08, 1.35), p=0.0007; I 2 12%, p=0.34). Sensitivity analysis by excluding one study (Rodriguez) showed that heterogeneity could be reduced while . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . maintaining significance. (RR 1. 25 (Table 4 ). However, CRP levels and these variables only included two studies ( Figure 7 ).

We only carried out subgroup analysis consisted of DVT only, PE only, and unspecified VTE group in correlation to ICU admission. Other subgroup analyses for mortality and mechanical ventilation were unable to be conducted due to two subgroups (DVT and VTE) contained less than two studies. As a result, the DVT only group was not associated with ICU admission (RR 2.47 (0.71, 8.59), p=0.16; I 2 54%, p=0.14). Whereas in contrast, higher ICU admission were significant in the PE only group (RR 1.75 (1.13, 2.69), p=0.01; I 2 74%, p=0.009) and in unspecified VTE group (RR 5.50 (2.09, 14.49), p<0.00001; I 2 0%, p=0.39). However, considerable heterogeneity between subgroups was noted (I 2 75.9%, p=0.02). (Figure 8 )

We did not perform publication bias in accordance to the Cochrane handbook reference which stipulates that the power of inverted funnel-plot analysis is too low to discriminate the chance from real asymmetry if the included studies are less than 10.(21)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . Coagulopathy and VTE in COVID-19 are an emerging phenomenon with devastating consequences and has been associated with poor prognosis in COVID-19.(22,23) Thus, it prompts International Society of Thrombosis and Haemostasis (ISTH) to publish interim guidelines for managing COVID-19's coagulopathy. (24) They recommend that all hospitalized COVID-19 patients, should be prophylactically anticoagulated.

The underlying factors contributed to VTE according Virchow's triad, which are venous stasis, activation of coagulation, and vascular dysfunction. (25) The first factor, venous stasis, is common due to immobilization in hospitalized patients, especially patients that reside in the ICU. Nonetheless, the incidence of VTE in ICU-admitted COVID-19 patients were higher compared to other diseases. (10, 11) The other two factors are culmination of COVID-19 infection. SARS-CoV-2 can infect different organs through angiotensin-converting enzyme 2 (ACE-2), a glycoprotein metalloprotease that are ubiquitously found in human organs, particularly the endothelial cells, which traversed multiple organs and the pneumocytes. (26, 27) The ensuing hypoxia caused by lung injury and ARDS in COVID-19 is a key factor of vascular fibrin deposition due to the increased early growth response-1 (Egr-1), which triggered tissue factor transcription/translation by mononuclear phagocytes and smooth muscle cells. (28) Furthermore, there is a role of bidirectional immunothrombosis, which is heightened inflammation will shift the balance to the procoagulant state by downregulating necessary anticoagulant pathways, while upregulating tissue factor expression necessary for thrombin generation. (29) In addition, SARS-CoV-2 downregulates ACE-2 after successfully infected cells, which is a counterregulatory enzyme of Angiotensin II (AngII) that maintains the reninangiotensin system (RAS) balance in check. (30) This condition leads to a prothrombotic milieu. Interaction of AngII with angiotensin II type 1 receptor (ATR-1) will activate transcription factors, which increased adhesion and accumulation of neutrophils and macrophages to endothelial cells, and ultimately these cells will release proinflammatory cytokines and chemokines. (31, 32) All of these will preserve the vicious cycle of inflammation and coagulopathy.

SARS-CoV-2 is also known to cause direct vascular injury via ACE-2 receptors. Case series of post mortem analysis of decedents due to COVID-19 confirmed diffuse endothelial inflammation, termed endothelitis, viral elements within endothelial cells, and inflammatory cell death.(33) Furthermore, morphologic and molecular changes from autopsied decedents due to COVID-19 ARDS showed severe endothelial injury with viruses present . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . intracellularly and disrupted cell membranes. Another hallmark feature was thrombosis and microangiopathy and intussusceptive angiogenesis, which was nine times and 2.7 times more common than patients with influenza.(34)

To the best of our knowledge, this is the first systematic review and meta-analysis that describes the clinical characteristics and outcomes associated with VTE in COVID-19

patients. The meta-analysis has shown that VTE was significantly associated with mortality compared to the non-VTE group after sensitivity analysis, by excluding Poyiadji It is well known that worse clinical presentations of COVID-19 disproportionately affect the older population and male gender. However, the pathomechanisms remain elusive.

In our meta-analysis, the male gender was associated with VTE. This result might explain, in part, why males were disproportionately affected. Nonetheless, men do have a higher risk of first and recurrent VTE compared to women, and it is hypothesized due to X or Y link mutation or mutation on a gene with a sex-specific effect. (36) In our meta analysis, VTE was associated with the older population after we performed sensitivity analysis, by excluding Poyiadji. (15) In his study, VTE occured in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. .

Artifoni et al. and Rodriguez et al. (13, 17) However, it is important to keep in mind that analysis from a population-based study of 25 years involving 2218 patients, with increasing age, there is a marked increase in VTE incidences in both sexes. (37) Previously, a meta-analysis by Tian, et al. found that higher WBC count, D-Dimer, CRP, and LDH levels were associated with mortality in COVID-19. (38) . These biomarkers serve as an indicator of heightened inflammation and organ damages. Thus, in the setting of marked inflammation, the bidirectional role of immunothrombosis plays a crucial part in VTE's pathomechanism. In our meta-analysis, higher WBC count, D-Dimer, CRP, and LDH levels were associated with VTE. However, the CRP variable gains significance after we only included two studies. Therefore, more prospective studies are needed.

On the other hand, our meta-analysis did not yield any association between VTE and comorbidities. Therefore, another likely explanation of why there is a higher burden of COVID-19 in patients with comorbidities.(30,39) Furthermore, it is not surprising that symptoms and signs other than dyspnea were not associated with VTE. Also, we believed that dyspnea in COVID-19 is not adequately sensitive to distinguish pulmonary embolism (VTE spectrum) from the lung injury, which is the main target organ of SARS-CoV-2.

We also did not find any association between platelet count and VTE, confirming findings that coagulopathy in COVID-19 is a distinct entity compared to disseminated intravascular coagulation (DIC). (40) The thrombosis phenomena in COVID-19 occurred on an earlier phase, thus do not reflect the state of consumptive coagulopathy. (7, 9, 41, 42) Finally, we can not confirm other analyzed variables that were and were not associated with COVID-19 due to only including two studies. Thus, more prospective studies are needed.

This systematic review and meta-analysis have several limitations. First, although the total subjects pooled from eight studies were adequate (n= 1237 subjects), it is worth noting that the reported VTE phenomena are not homogeneous. Two studies reported VTE, four studies reported PE only, and two studies reported DVT only. Moreover, not all of the studies reported the outcome of interest. Thus, we can only perform a subgroup analysis for ICU admission. Second, due to many missing data from included studies, more studies are needed to confirm meta-analysis findings that consisted of two studies. Thus, we can not fully elucidate the representative clinical characteristics associated with VTE in COVID-19

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . patients. Third, most of the studies were from western countries, so it can not be generalized for all populations. Finally, the included studies were predominantly retrospective design.

Venous thromboembolism in patients with COVID-19 contributed significantly to higher inhospital mortality, ICU admission and the need of mechanical ventilation. Additionally, male gender, older age, as well as higher levels of WBC count, D-Dimer, and LDH were associated with increased risks of developing VTE in COVID-19.

The authors are grateful to Quinta Febryani Handoyono, MD, for her assistance on the figure design.

The authors declare that there is no conflict of interest . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 16, 2020. . patients complicated with PE and VTE, were associated with higher ICU admission.

However, considerable heterogenity and subgroup differences were noted.

COVID-19 coagulopathy: an evolving story

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Vander Heide RS. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans [Internet]. Pathology

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Acute Pulmonary Embolism and COVID-19

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Acute Pulmonary Embolism In Non-Hospitalized Covid-19 Patients Referred To CTPA By Emergency Department

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary embolism in patients with Covid-19 pneumonia

Hematological findings and complications of COVID 19

Fatal Pulmonary Thromboembolism in SARS-CoV-2-Infection

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Basic Mechanisms and Pathogenesis of Venous Thrombosis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

Hypoxemia-Induced Activation of the Procoagulant Pathways and the Pathogenesis of Ischemia-Associated Thrombosis

Inflammation and coagulation

COVID-19, diabetes mellitus and ACE2: The conundrum

COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment

Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism: A 25-Year Population-Based Study

Predictors of mortality in hospitalized COVID 19 patients: A systematic review and meta analysis

The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy